Xeris Pharmaceuticals Stock Current Valuation
| XERS Stock | USD 3.29 0.05 1.50% |
Valuation analysis of Xeris Pharmaceuticals helps investors to measure Xeris Pharmaceuticals' intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns. Enterprise Value is likely to gain to about 458.6 M in 2025, despite the fact that Enterprise Value Over EBITDA is likely to grow to (22.34). Fundamental drivers impacting Xeris Pharmaceuticals' valuation include:
Overvalued
Today
Please note that Xeris Pharmaceuticals' price fluctuation is unstable at this time. Calculation of the real value of Xeris Pharmaceuticals is based on 3 months time horizon. Increasing Xeris Pharmaceuticals' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Xeris stock is determined by what a typical buyer is willing to pay for full or partial control of Xeris Pharmaceuticals. Since Xeris Pharmaceuticals is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Xeris Stock. However, Xeris Pharmaceuticals' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 3.29 | Real 2.77 | Target 4.77 | Hype 3.29 | Naive 3.37 |
The intrinsic value of Xeris Pharmaceuticals' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Xeris Pharmaceuticals' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Xeris Pharmaceuticals helps investors to forecast how Xeris stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Xeris Pharmaceuticals more accurately as focusing exclusively on Xeris Pharmaceuticals' fundamentals will not take into account other important factors: Xeris Pharmaceuticals Company Current Valuation Analysis
Xeris Pharmaceuticals' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Xeris Pharmaceuticals Current Valuation | 692.04 M |
Most of Xeris Pharmaceuticals' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Xeris Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Xeris Current Valuation Driver Correlations
Understanding the fundamental principles of building solid financial models for Xeris Pharmaceuticals is extremely important. It helps to project a fair market value of Xeris Stock properly, considering its historical fundamentals such as Current Valuation. Since Xeris Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Xeris Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Xeris Pharmaceuticals' interrelated accounts and indicators.
Click cells to compare fundamentals
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Xeris Pharmaceuticals has a Current Valuation of 692.04 M. This is 95.18% lower than that of the Pharmaceuticals sector and 85.1% lower than that of the Health Care industry. The current valuation for all United States stocks is 95.84% higher than that of the company.
Xeris Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Xeris Pharmaceuticals' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Xeris Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Xeris Pharmaceuticals by comparing valuation metrics of similar companies.Xeris Pharmaceuticals is currently under evaluation in current valuation category among its peers.
Xeris Pharmaceuticals Current Valuation Drivers
We derive many important indicators used in calculating different scores of Xeris Pharmaceuticals from analyzing Xeris Pharmaceuticals' financial statements. These drivers represent accounts that assess Xeris Pharmaceuticals' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Xeris Pharmaceuticals' important valuation drivers and their relationship over time.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Market Cap | 209.8M | 231.5M | 180.4M | 323.5M | 291.2M | 305.7M | |
| Enterprise Value | 230.6M | 307.6M | 256.5M | 485.3M | 436.8M | 458.6M |
Xeris Pharmaceuticals ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Xeris Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Xeris Pharmaceuticals' managers, analysts, and investors.Environmental | Governance | Social |
Xeris Fundamentals
| Return On Equity | -6.17 | ||||
| Return On Asset | -0.087 | ||||
| Profit Margin | (0.34) % | ||||
| Operating Margin | (0.24) % | ||||
| Current Valuation | 692.04 M | ||||
| Shares Outstanding | 149.08 M | ||||
| Shares Owned By Insiders | 3.92 % | ||||
| Shares Owned By Institutions | 43.99 % | ||||
| Number Of Shares Shorted | 10.19 M | ||||
| Price To Book | 3.34 X | ||||
| Price To Sales | 2.62 X | ||||
| Revenue | 163.91 M | ||||
| Gross Profit | 152.44 M | ||||
| EBITDA | (23.73 M) | ||||
| Net Income | (62.26 M) | ||||
| Cash And Equivalents | 111.55 M | ||||
| Cash Per Share | 0.82 X | ||||
| Total Debt | 229.19 M | ||||
| Debt To Equity | 1.87 % | ||||
| Current Ratio | 2.50 X | ||||
| Book Value Per Share | (0.19) X | ||||
| Cash Flow From Operations | (47.02 M) | ||||
| Short Ratio | 6.21 X | ||||
| Earnings Per Share | (0.43) X | ||||
| Target Price | 4.77 | ||||
| Number Of Employees | 377 | ||||
| Beta | 1.29 | ||||
| Market Capitalization | 490.48 M | ||||
| Total Asset | 322.6 M | ||||
| Retained Earnings | (617.02 M) | ||||
| Working Capital | 61.07 M | ||||
| Net Asset | 322.6 M |
About Xeris Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Xeris Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Xeris Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Xeris Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Xeris Stock Analysis
When running Xeris Pharmaceuticals' price analysis, check to measure Xeris Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Xeris Pharmaceuticals is operating at the current time. Most of Xeris Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Xeris Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Xeris Pharmaceuticals' price. Additionally, you may evaluate how the addition of Xeris Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.